EUVIMEDEUVIMED entdecken
LeserbriefKommentarOpen Access · CC BY-NC-ND 4.0

Valproate induced carnitine deficiency and hyperammonaemia

Eamon P McCarron

Clinical Medicine · 2023-07 · 23 (4) · 429

DOI: 10.7861/clinmed.let.23.4.1 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Medicine, 2023-07. Verfasst von Eamon P McCarron. Beteiligte Einrichtung: Queen's University Belfast, Belfast, Northern Ireland. Hauptthemen laut MEDLINE: Hyperammonemia, Epilepsy, Amino Acid Metabolism, Inborn Errors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Editor – I read with interest the article by Yu-E et al, [1][1] and the earlier case by Camilleri et al. [2][2] Hyperammonemia is a recognised complication of treatment with valproic acid (VPA) or its sodium salt (sodium valproate) and although the mechanism is not fully understood, secondary

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperammonemiaEpilepsyAmino Acid Metabolism, Inborn ErrorsHumansValproic AcidAnticonvulsantsCarnitine

Substanzen

Valproic AcidAnticonvulsantsCarnitine

Autor:innen und Institutionen

  • Queen's University Belfast, Belfast, Northern Ireland.

Zitieren

APA

McCarron, E. P. (2023). Valproate induced carnitine deficiency and hyperammonaemia. Clinical Medicine, 23(4), 429. https://doi.org/10.7861/clinmed.let.23.4.1

Vancouver

McCarron EP. Valproate induced carnitine deficiency and hyperammonaemia. Clinical Medicine. 2023;23(4):429. doi:10.7861/clinmed.let.23.4.1

BibTeX
@article{McCarron2023,
  author = {McCarron, Eamon P},
  title = {Valproate induced carnitine deficiency and hyperammonaemia},
  journal = {Clinical Medicine},
  year = {2023},
  volume = {23},
  number = {4},
  pages = {429},
  doi = {10.7861/clinmed.let.23.4.1}
}
Kostenlos starten →